Clinical Trials Browser

TQ-B3525 × Clear all

NCT03510767 2023-04-14

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Phase 1 Unknown

Lymphoma, Recurrence

NCT04610970 2021-08-18

A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）

Phase 2 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT04836663 2021-06-01

A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors

Phase 2 Unknown

Uterine Cervical Neoplasms, Ovarian Neoplasms

NCT04690725 2020-12-31

TQBSP

Phase 1/2 Unknown

Chondrosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT04615468 2020-11-04

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）

Phase 2 Unknown

Lymphoma, T-Cell, Peripheral

NCT04398953 2020-09-11

A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)

Phase 2 Unknown

Lymphoma, Mantle-Cell

NCT04324879 2020-07-01

A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

Phase 2 Unknown

Lymphoma, Follicular

NCT04355520 2020-04-21

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Phase 1/2 Unknown

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer